Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166225 | 0.93 | PTGS2 (0.41) | DRD2PTGS2DRD1DRD3DRD4 | |
| SCHEMBL7023211 | 0.90 | DRD2 (0.42) | DRD2DRD1DRD3DRD4DRD5 | |
| Hydrogen Sulfide SCHEMBL27520693 | 0.90 | PTGS2 (0.46) | DRD2PTGS2DRD1DRD3DRD4 | |
| Iodide SCHEMBL8733602 | 0.90 | PTGS2 (0.46) | DRD2PTGS2DRD1DRD3DRD4 | |
| SCHEMBL16926997 | 0.89 | DRD2 (0.41) | DRD2DRD1DRD3DRD4DRD5 | |
| SCHEMBL28551762 | 0.89 | PTPN1 (0.42) | DRD2DRD1DRD3DRD4DRD5 | |
| SCHEMBL1423686 | 0.89 | CYP11B1 (0.41) | DRD2PTGS2DRD1DRD3DRD4 | |
| Iodide SCHEMBL8737221 | 0.87 | LMNA (0.43) | DRD2PTGS2DRD1DRD3DRD4 | |
| Iodide SCHEMBL21220125 | 0.87 | PTGS2 (0.39) | DRD2PTGS2DRD1DRD3DRD4 | |
| Iodide SCHEMBL8735153 | 0.87 | PTGS2 (0.39) | DRD2PTGS2DRD1DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1832922-A | Sulfonyl-substituted N- (biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO INC (US) | 2006-09-13 | — | — | CN | claimed |
| EP-4721534-A1 | COMPOUND, ORGANIC LIGHT EMITTING DIODE, AND DISPLAY DEVICE | Novaled GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246197-A1 | COMPOUND, ORGANIC LIGHT EMITTING DIODE, AND DISPLAY DEVICE | NOVALED GMBH (DE) | 2024-12-05 | — | — | WO | disclosed |
| CN-118852159-A | Heterogeneous palladium-catalyzed selective bell wood coupling reaction and application thereof in Wilmofini intermediate synthesis | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-10-29 | — | — | CN | disclosed |
| CN-112469690-B | Method for producing arylamines | 默克专利有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240083926-A1 | PHOSPHORUS COMPOUNDS AND METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-03-14 | — | — | US | disclosed |
| CN-113527121-B | C (sp3) -C (sp2) Bond construction method and preparation method of beta-aryl amino acid | 河北科技大学 | 2023-01-17 | — | — | CN | disclosed |
| EP-3818038-B1 | PROCESS FOR THE PRODUCTION OF ARYLAMINES | MERCK PATENT GMBH (DE) | 2022-08-03 | — | — | EP | disclosed |
| EP-4028381-A1 | CANNABINOID DERIVATIVES, PRECURSORS AND USES | Kare Chemical Technologies Inc. (CA) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022132048-A1 | PHOSPHORUS COMPOUNDS AND METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-06-23 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0813560-A2 | SOLUBLE FLUORINATED POLY-P-PHENYLENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996028491-A1 | SOLUBLE FLUORINATED POLY-P-PHENYLENES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5530150-A | HAVING PHOSPHINE AND PHOSPHITE GROUPS IN SAME MOLECULE; CATALYST SELECTIVITY | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-06-25 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083926-A1 | PHOSPHORUS COMPOUNDS AND METHODS THEREOF | PHPT1, PTH1R, SOST | DRD2 3687/4885PTGS2 2114/4885DRD1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.